SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

Table 9 Change in hepatic fat in individual studies

Study	Parameter	Group	Baseline	Study completion	P value	P value between groups
Kuchay et al[11]	MRI-PDFF	Empagliflozin	16.2 (7)	11.3 (5.3)	< 0.0001	< 0.0001
		Control	16.4 (7.3)	15.5 (6.7)	0.054
Ito et al[12]	L/S ratio	Ipragliflozin	0.8 (0.2)	1.0 (0.2)	< 0.05	0.90
		Pioglitazone	0.8 (0.3)	1.0 (0.2)	< 0.05
Shibuya et al[13]	L/S ratio	Luseogliflozin	0.9 (0.6-1.0)	1.0 (0.8-1.2)	0.0008	0.00002
		Metformin	1.0 (0.8-1.1)	0.9 (0.7-1.0)	0.017
Eriksson et al[14]	MRI-PDFF	Placebo	15.1 (6.5)	-0.6 (1.9)1	-	-
		Omega-3 CA	22.2 (11.0)	-3.2 (2.9)1	-	Non-significant2
		Dapagliflozin	17.3 (9.1)	-2.2 (3.3)1	-	Non-significant2
		O + D	17.8 (9.2)	-3.2 (3.5)1	-	< 0.052
Sumida et al[18]	MRI-HFF	Luseogliflozin	21.5 (7.2)	15.7 (6.8)	< 0.001	-

¹Change from baseline.

² Compared to placebo.

MRI-PDFF: Magnetic resonance imaging-derived proton density fat fraction; L/S ratio: Liver/spleen attenuation ratio; MRI-HFF: Magnetic resonance imaging-hepatic fat fraction; CA: Carboxylic acid; O + D: Omega-3 CA + Dapagliflozin.